October 4, 2016 – Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.
Category: Uncategorized
Privacy Analytics Acquired by IMS Health
May 26, 2016 – The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.
Trillium Therapeutics Acquires Fluorinov Pharma
January 28, 2016 – Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.
Read More from Trillium Therapeutics Acquires Fluorinov Pharma
FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics
December 16, 2015 – FACIT’s investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.
FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia
December 8, 2015 – FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.
Read More from FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
November 19, 2015 – Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.
OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers
October 14, 2015 – OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers.
Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial
July 10, 2015 – Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.
Read More from Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial
Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors
May 26, 2015 – Mr. Beshar’s appointment strengthens Fluorinov’s leadership team, adding financial and pharmaceutical industry expertise as Fluorinov accelerates its clinical development activities.
Read More from Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors
Turnstone Biologics Inc. to Accelerate Clinical and Commercial Translation of Cancer Immunotherapies
May 4, 2015 – FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system.